Inspira Technologies Oxy B.H.N. Ltd (IINN) Stock Price, Quote & News

Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacturing, and marketing of proprietary life support technologies for the treatment of acute respiratory failure in Israel. It offers INSPIRA ART100, a life support system used in procedures requiring cardiopulmonary bypass for six hours or less. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 4 623 0333

Website: inspira-technologies.com

Address:

2 Ha-Tidhar St., Ra'anana, Israel

IPOWarrior Apr. 24 at 8:30 PM

$IINN we got another week or so to pick up cheapies, volume is pretty low, but traders keep hopping over my low-ball bids. This is pretty much right alongside, if not lower, than where the insiders - who have been holding their IPO shares plus additional earned sweat equity since then - are positioned.

1 · Reply

JakBurton Apr. 24 at 6:19 PM

$IINN The video below is three years old and the tech has developed significantly since

0 · Reply

JakBurton Apr. 24 at 6:13 PM

$IINN https://youtu.be/6DAQcrkbDLo?si=TRqXR9apBitOT9Su

0 · Reply

nothingsnew Apr. 24 at 3:05 PM

$IINN

0 · Reply

GJ_Rockabilt Apr. 24 at 9:48 AM

$IINN Sleepyheads...

0 · Reply

GJ_Rockabilt Apr. 23 at 11:40 PM

$IINN

1 · Reply

JakBurton Apr. 23 at 9:50 PM

$IINN Buy and Hold When the name change becomes official, Nasdaq assigns a new CUSIP, and management updates their operational classification. The algorithms immediately rip the ticker out of the "Biotech" bucket and drop it directly into the "Quantum/Tech Infrastructure" bucket. The Re-Rating: The computers physically stop applying a 1x to 2x revenue multiple based on medical hardware, and instantly begin applying a 10x to 15x SaaS (Software as a Service) multiple based on the AME quantum technology.

0 · Reply

JakBurton Apr. 23 at 9:37 PM

$IINN ha

0 · Reply

THE_Perfusionist Apr. 23 at 6:19 PM

$IINN

0 · Reply

OGLUCIDBULL Apr. 23 at 4:13 PM

$IINN this naked short rat is maxxing out now with that infinity short/ chart manipulation.

0 · Reply

Inspira Completes Commercial Deployment of its AME System at a Tier-1 U.S. Defense Entity

Apr 14, 2026, 8:01 AM EDT - 11 days ago

Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion

NNDM SSYS

Apr 13, 2026, 8:16 AM EDT - 12 days ago

Inspira Begins AME Technology Implementation Process with One of the World's 10 Largest U.S. Based Companies

Apr 6, 2026, 9:01 AM EDT - 19 days ago

Inspira Enters Quantum Computing Sector, Targeting a Critical Connectivity Bottleneck with Newly Acquired AME Platform

Apr 6, 2026, 8:31 AM EDT - 19 days ago

Inspira Technologies Announces Acquisition of the AME Platform from Nano Dimension

Mar 31, 2026, 8:16 AM EDT - 25 days ago

Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase

Mar 26, 2026, 4:30 PM EDT - 4 weeks ago

Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates

Feb 25, 2026, 4:10 PM EST - 2 months ago

Inspira Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

Feb 18, 2026, 8:32 AM EST - 2 months ago

Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State

Feb 17, 2026, 8:00 AM EST - 2 months ago

Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks

Feb 12, 2026, 4:01 PM EST - 2 months ago

Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

Feb 3, 2026, 9:22 AM EST - 2 months ago

Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market

Jan 21, 2026, 8:50 AM EST - 3 months ago

Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders

Jan 5, 2026, 10:46 AM EST - 3 months ago

CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation

Jan 5, 2026, 9:30 AM EST - 3 months ago

Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation

Dec 23, 2025, 8:30 AM EST - 4 months ago

Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones

Dec 15, 2025, 8:30 AM EST - 4 months ago

Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution

Dec 3, 2025, 8:43 AM EST - 5 months ago

Inspira Technologies Announces Strategic Leap in Lab Capabilities – Accelerating Next-Generation Diagnostics and Blood Technology

Nov 13, 2025, 9:00 AM EST - 5 months ago

Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission

Nov 6, 2025, 9:10 AM EST - 6 months ago

Inspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion

Oct 22, 2025, 8:30 AM EDT - 6 months ago

Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira's Global Ecosystem

Oct 21, 2025, 9:05 AM EDT - 6 months ago

Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm

Oct 1, 2025, 8:00 AM EDT - 7 months ago

Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

Sep 11, 2025, 9:30 AM EDT - 8 months ago

Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance

Aug 22, 2025, 8:45 AM EDT - 8 months ago

Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market

Aug 7, 2025, 9:44 AM EDT - 9 months ago

Inspira Clarifies Routine Nature of Registration Statement on Form F-3 Filing Performed Every Three Years

Jul 31, 2025, 9:15 AM EDT - 9 months ago

Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives

Jul 18, 2025, 8:10 AM EDT - 10 months ago

Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 10, 2025, 9:25 AM EDT - 10 months ago

Inspira Achieves All Key Objectives in Previously Announced Government Talks, Forging a Pathway to National Adoption and Global Scale-Up of the ART100

Jul 7, 2025, 8:50 AM EDT - 10 months ago

Inspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework

Jul 2, 2025, 9:23 AM EDT - 10 months ago

Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase

Jun 11, 2025, 9:10 AM EDT - 11 months ago

Inspira's ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions

Jun 5, 2025, 11:15 AM EDT - 11 months ago

CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority

Jun 5, 2025, 9:15 AM EDT - 11 months ago

Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority

May 29, 2025, 9:15 AM EDT - 11 months ago

Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System

May 7, 2025, 8:45 AM EDT - 1 year ago

INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing

Apr 15, 2025, 9:15 AM EDT - 1 year ago

Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Inspira Technologies Announces Successful Installation of INSPIRA ART100 Systems in Premier U.S. Hospital

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Inspira Technologies' Innovative Life-Support System to be Showcased at AmSECT 63rd International Conference 2025 in San Diego

Mar 18, 2025, 1:17 PM EDT - 1 year ago

PESG Report: Inspira Technologies' AI-Powered Respiratory System Could Revolutionize Care for 20 Million Annual ICU Patients in Combined $25+ Billion Market

Mar 14, 2025, 7:00 AM EDT - 1 year ago

Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care

Mar 13, 2025, 4:30 PM EDT - 1 year ago

Inspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates

Mar 5, 2025, 8:46 AM EST - 1 year ago

PESG Report: Inspira Technologies Breaks new Ground with Positive Clinical Data for AI-Powered Blood Sensor Exceeding Expectations

Mar 4, 2025, 8:30 AM EST - 1 year ago

Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy

Feb 11, 2025, 7:00 AM EST - 1 year ago

Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections

Feb 6, 2025, 8:27 AM EST - 1 year ago

PESG Report: Inspira Technologies Strengthens its AI-Powered Blood Sensor with new Capabilities, Intends to Share Clinical Findings Soon

Feb 5, 2025, 8:30 AM EST - 1 year ago

Inspira Technologies Integrates New Oxygenation Indicator into AI-Powered HYLA Blood Sensor

IPOWarrior Apr. 24 at 8:30 PM

1 · Reply

JakBurton Apr. 24 at 6:19 PM

$IINN The video below is three years old and the tech has developed significantly since

0 · Reply

JakBurton Apr. 24 at 6:13 PM

$IINN https://youtu.be/6DAQcrkbDLo?si=TRqXR9apBitOT9Su

0 · Reply

nothingsnew Apr. 24 at 3:05 PM

$IINN

0 · Reply

GJ_Rockabilt Apr. 24 at 9:48 AM

$IINN Sleepyheads...

0 · Reply

GJ_Rockabilt Apr. 23 at 11:40 PM

$IINN

1 · Reply

JakBurton Apr. 23 at 9:50 PM

0 · Reply

JakBurton Apr. 23 at 9:37 PM

$IINN ha

0 · Reply

THE_Perfusionist Apr. 23 at 6:19 PM

$IINN

0 · Reply

OGLUCIDBULL Apr. 23 at 4:13 PM

$IINN this naked short rat is maxxing out now with that infinity short/ chart manipulation.

0 · Reply

Wizzard88 Apr. 23 at 3:58 PM

$IINN You kidding me ?!!

2 · Reply

Wizzard88 Apr. 23 at 3:37 PM

$IINN wtf is happening today ?

0 · Reply

IPOWarrior Apr. 23 at 1:26 PM

$IINN like I said many times when the price has been at absurdly low levels: they're loading at low price points. https://www.sec.gov/Archives/edgar/data/1837493/000118518526001469/xslF345X06/ownership.xml The CBO they poached from NNDM along with the quantum-tech is getting his shares/options while the price is low: makes sense: he gets more shares. Once those are issued to him along with anyone else they need to feed on this round, then they can bring it back over $1 for compliance, and then boost it from there on PR and business developments.

1 · Reply

JakBurton Apr. 23 at 11:44 AM

$IINN back to 1$

1 · Reply

nothingsnew Apr. 23 at 10:13 AM

$IINN

0 · Reply

OGLUCIDBULL Apr. 22 at 5:13 PM

$IINN shorts engaged in trading fraud here. I can’t get locates but they can sell 500k short a day and somehow illegally clear in dark pool. I would love to halt the ticker pull the trades and then you can follow right to the trader and slam their asses in jail. Yeehaw!

0 · Reply

JakBurton Apr. 22 at 1:48 PM

$IINN with this float size and quantum revenue multipliers, we could see $RGTI $IONQ type numbers

2 · Reply

Wizzard88 Apr. 22 at 1:41 PM

$IINN Give us 2+ 🙏🙏🙏🙏

0 · Reply

CentsChaser Apr. 22 at 1:07 PM

$IINN $ELAB

0 · Reply

JakBurton Apr. 22 at 11:53 AM

$IINN

0 · Reply

johnnylawrencecobra Apr. 22 at 12:36 AM

$CLWT $ENVB $GIFT $IINN

0 · Reply

GJ_Rockabilt Apr. 21 at 6:10 PM

$RGTI If you're interested in Scaling Quantum, then DD $IINN , IINNW. That's all, for now.

0 · Reply

Market Cap	6.81M
Revenue (ttm)	290,000.00
Net Income (ttm)	-13.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,558.62%
Debt to Equity Ratio	0.00

Volume	144,700
Avg Vol	288,786
Day's Range	N/A - N/A
Shares Out	12.62M
Stochastic %K	40%
Beta	2.33
Analysts	Sell
Price Target	$5.00